Skip to main content

Ethylphenidate Facts

Stimulant; Phenidate; Dopamine reuptake inhibitor

Description

Ethylphenidate (ethyl 2-phenyl-2-piperidin-2-ylacetate) — Gogaine, Burst — is a synthetic stimulant of the phenidate class. It blocks dopamine reuptake in the brain, producing stimulation, euphoria, and a strong drive to redose.

Subjective effects include Stimulation, Euphoria, focus enhancement, and a powerful urge to redose. The experience is more recreational than functional — longer and less intensely euphoric than cocaine, and less useful for cognition than methylphenidate, with the drive to re-administer often outrunning the reward.[1][2]

Dependence liability is moderate; nearly all documented fatalities involved combinations with depressants.[3][4] The dominant risk is the compulsive redosing urge — escalating doses compound cardiovascular strain and psychological destabilization, and the drive to re-administer often persists after the reward has faded.[5]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 10 mgLight20 – 40 mgCommon40 – 80 mgStrong80 – 120 mgHeavy120+ mg

Starts in 40 – 120 minLasts 4 – 7 hoursAfter-effects 2 – 6 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Moderate
Physical dependence
Low
Psychological dependence
Moderate
Withdrawal
Mild
Compulsive redosing
High

Tolerance

Builds
Moderate
Fully resets after
10.5 days
Carries over to
methylphenidate; amphetamine; cocaine; dopaminergic stimulants

Effectslikely at a common dose

Body
Stimulation; Wakefulness; +26 possible, including Vasoconstriction, Heart rate perception changes, Insomnia
Thinking
none likely · 19 possible, including Compulsive redosing urge, Decision impairment
Feeling
none likely · 9 possible, including Anxiety, Paranoia, Depression
Self
none likely · 7 possible, including Craving, Ego inflation
Awareness
One-pointedness (ekaggata); Sustained attention (vicara); +1 possible

Who shouldn't take it

Absolute
Cardiovascular disease; Uncontrolled hypertension; Cardiac arrhythmia history; Pregnancy and lactation; MAOI co-administration; Tramadol co-administration
Relative
MDMA co-administration; Seizure disorder; Uncontrolled thyroid disease

Combinations62 recorded

Lethal (2)
Ibogaine; Tramadol
Dangerous (32)
Alpha-2 adrenergic receptor antagonist; Amphetamines; Benzodiazepines, Barbiturates; Ephedrine, Pseudoephedrine; Local anesthetics; MAOIs; MDMA, Amphetamines; MDMA, MDA; NDRIs (Wellbutrin); NRIs; Opioids; Stimulants; Anticholinergics; Antipsychotics; Buspirone; Caffeine; Clonidine, Guanfacine; Dopamine agonists; DXM; GHB, Baclofen; GHB, GBL; Ketamine, DXM, PCP; Lithium; NSAIDs; and 8 more, see full page
Caution (25)
See full page: psychedex.org/substances/ethylphenidate
Not graded (3)
Not listed never means safe.

Seek help immediately if

  • Chest pain; racing, pounding, or irregular heartbeat
  • Very high body temperature; heavy sweating; hot, flushed skin
  • Severe agitation, paranoia, panic, or confusion
  • Severe headache; muscle rigidity or twitching
  • Seizures
  • Signs of stroke — face drooping, one-sided weakness, slurred speech
  • Difficulty breathing; collapse or unconsciousness

What to do

  1. Call emergency services for chest pain, overheating, seizure, or unresponsiveness
  2. Move them to a cool, quiet place and reduce stimulation
  3. Cool the body — remove excess clothing, apply cool damp cloths, fan them
  4. Keep them calm; reassure — panic worsens the cardiovascular strain
  5. If seizing, protect from injury (don't restrain); recovery position afterward
  6. Monitor breathing and be ready to give rescue breaths / CPR

Most stimulant overdoses settle with cooling, a calm environment, and time. The medical danger is hyperthermia, cardiac events (arrhythmia, heart attack, stroke), and seizures — get help immediately if any appear.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Soussan C, Kjellgren A (2015) "Chasing the high" - experiences of ethylphenidate as described on international internet forums. — Substance Abuse: Research and Treatment doi:10.4137/sart.s22495
  2. [2]
    ^Patrick KS, Corbin TR, Murphy CE (2014) Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker. — Journal of Pharmaceutical Sciences doi:10.1002/jps.24202
  3. [3]
    ^Maskell PD, Smith PR, Cole R, Hikin L, Morley SR (2016) Seven fatalities associated with ethylphenidate. — Forensic Science International doi:10.1016/j.forsciint.2015.12.045
  4. [4]
    ^Parks C, McKeown D, Torrance HJ (2015) A review of ethylphenidate in deaths in east and west Scotland. — Forensic Science International doi:10.1016/j.forsciint.2015.08.008
  5. [5]
    ^Robins MT, Blaine AT, Ha JE, Brewster AL, van Rijn RM (2019) Repeated Use of the Psychoactive Substance Ethylphenidate Impacts Neurochemistry and Reward Learning in Adolescent Male and Female Mice. — Frontiers in Neuroscience doi:10.3389/fnins.2019.00124
Print version
Report an issue